

Applicants: Gotwals, et al.
Application No.: 09/996,738
Filed: November 30, 2001
Page 2 of 9

Docket No. A076US

--More particularly, the invention provides a method for the treatment of an inflammatory disorder in a subject comprising administering to the subject a pharmaceutical composition comprising an effective amount of an $\alpha 1\beta 1$ function blocking antibody or a fragment of the antibody, wherein the $\alpha 1\beta 1$ function blocking antibody or fragment is capable of binding an epitope of VLA-1 comprising amino acid residues 91-96, Val-Gln-Arg-Gly-Gly-Arg-. --

In the specification, at page 6, line 11, replace the existing text with the following:
--Figure 15. Figure 15 illustrates the amino acid sequence of the human $\alpha 1$ -I integrin polypeptide sequence. The amino acid sequence of the epitope for the anti- $\alpha 1$ -I domain blocking mAbs (SEQ ID NO:8) is shown in the box.--

In the specification, at page 9, line 19, replace the existing text with the following:
--An $\alpha 1\beta 1$ function blocking antibody as used herein refers to an antibody that binds to the $\alpha 1$ -I domain, specifically at an epitope identified by amino acids 91-96 of Figure 15, and that blocks $\alpha 1\beta 1$ function as tested for, by example, the ability to inhibit K562- $\alpha 1$ dependent adhesion to Collagen IV (see Example 15).--

In the Claims

Amend claim 1 as follows:

--1. (Once amended) A method for the treatment of arthritis comprising administering to a subject suffering from arthritis a composition comprising a function blocking antibody or a fragment of said antibody, capable of binding an epitope of VLA-1 wherein the epitope comprises amino acid residues 91-96 of Figure 15 (SEQ ID NO:8), and in an amount effective to provide a decrease in arthritic score of about 65% or greater when compared to a control antibody treated subject.--